FMS · Fresenius Medical Care AG
$22.30
+0.29% last session
End-of-day data · close of 2026-09-11
Market cap
$12B
Enterprise value
$23B
Trailing P/E
11.6
Forward P/E
7.1
Dividend yield
4.0%
Beta
0.83
Avg volume
1M
Employees
107K
Daily Change %
0.29%
5 Days Change
-1.46%
10 Days Change
-1.80%
30 Days Change
-6.45%
60 Days Change
-7.04%
Month to Day Change
-1.80%
Year to Day Change
-2.48%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — FMS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-06
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-06 | Bernstein | Maintains | Market Perform | $25.50 → $25.80 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 31 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.3% below the 50-day MA ($23.80).
- Price vs 200-day MA: Trading 1.2% below the 200-day MA ($22.56).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.07) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($19.41) and high ($26.35).
FMS Price Chart
Loading chart for FMS…
Fundamentals
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
More in Medical Care Facilities
HCA
HCA Healthcare, Inc.
$93B -9.3% YTD
THC
Tenet Healthcare Corporation
$21B 35.4% YTD
EHC
Encompass Health Corporation
$12B 15.1% YTD
DVA
DaVita Inc.
$12B 61.1% YTD
UHS
Universal Health Services, Inc.
$10B -19.1% YTD
ENSG
The Ensign Group, Inc.
$10B -1.3% YTD
CHE
Chemed Corp
$7B 21.7% YTD
PACS
PACS Group, Inc.
$7B 16.2% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.